If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Garijo will be the first woman to lead Sanofi in its history
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Subscribe To Our Newsletter & Stay Updated